Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zagociguat SCHEMBL21332996 | 0.99 | AR (0.34) | ARPDE5APDE4APDE1APDE1B | |
| Zagociguat SCHEMBL21333483 | 0.97 | PDE5A (0.35) | ARPDE5APDE4APDE1APDE1B | |
| Zagociguat SCHEMBL21332963 | 0.97 | PDE5A (0.33) | ARPDE5APDE4APDE1APDE1B | |
| Zagociguat SCHEMBL21332766 | 0.95 | PDE5A (0.34) | ARPDE5APDE4APDE1APDE1B | |
| Zagociguat SCHEMBL21332705 | 0.94 | PDE5A (0.33) | ARPDE5APDE4APDE1APDE1B | |
| SCHEMBL19922726 | 0.92 | EPHB4 (0.32) | EPHB4KDRTEK | |
| SCHEMBL19922775 | 0.92 | AR (0.33) | ARALDH1A1KDM4ETP53SMN1; SMN2 | |
| Zagociguat SCHEMBL21333489 | 0.92 | MEN1 (0.33) | ARPDE5APDE4APDE1APDE1B | |
| SCHEMBL26415379 | 0.89 | AR (0.34) | ARALDH1A1KDM4EKDM5BTP53 | |
| Zagociguat SCHEMBL21332823 | 0.89 | EPHB4 (0.32) | ARPDE5APDE4APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2025-04-10 | — | — | US | claimed |
| US-12122782-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2024-10-22 | — | — | US | claimed |
| EP-3762389-B1 | CRYSTALLINE FORMS OF AN SGC STIMULATOR | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | claimed |
| US-20230095799-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | TISENTO THERAPEUTICS INC. | 2023-03-30 | — | — | US | claimed |
| US-11466015-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | claimed |
| US-20210115050-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | TISENTO THERAPEUTICS INC. | 2021-04-22 | — | — | US | claimed |
| EP-3762389-A1 | CRYSTALLINE FORMS OF AN SGC STIMULATOR | Cyclerion Therapeutics, Inc. (US) | 2021-01-13 | — | — | EP | claimed |
| WO-2019173551-A1 | CRYSTALLINE FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | claimed |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250326761-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2025-04-10 | — | — | US | disclosed |
| CN-111836811-B | Method for preparing soluble guanylate cyclase stimulators | 帝善多制药公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3507291-A1 | FUSED BICYCLIC SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045276-A1 | FUSED BICYCLIC SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018045276-A1 | FUSED BICYCLIC SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115050-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | GUCY1A2, GUCY1B2, GUCY1A1 | AR 4406/4885PDE5A 8/4885PDE4A 16/4885 |
| US-20250326761-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | AR 4543/4885PDE5A 12/4885PDE4A 16/4885 |
| US-20180065971-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | AR 4543/4885PDE5A 12/4885PDE4A 16/4885 |
| US-12122782-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | GUCY1A2, GUCY1B2, GUCY1A1 | AR 3911/4885PDE5A 7/4885PDE4A 15/4885 |
| US-20230095799-A1 | CRYSTALLINE FORMS OF AN sGC STIMULATOR | GUCY1A2, GUCY1B2, GUCY1A1 | AR 4406/4885PDE5A 8/4885PDE4A 16/4885 |
| US-11466015-B2 | Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators | GUCY1A2, GUCY1B2, GUCY1A1 | AR 3911/4885PDE5A 7/4885PDE4A 15/4885 |
| US-20260116886-A1 | DEUTERATED sGC STIMULATORS | PDE2A, PRKG1, GUCY1A2 | AR 2852/4885PDE5A 4/4885PDE4A 20/4885 |
| US-20250115611-A1 | CRYSTALLINE FORMS OF 8-(2-FLUOROBENZYL)-6-(3-(TRIFLUOROMETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO[1,2-a]PYRAZINE AS sGC STIMULATORS | GUCY1A2, GUCY1B2, GUCY1A1 | AR 3911/4885PDE5A 7/4885PDE4A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.